Sold as Anzemet. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Dolasetron Mesylate (sold as Anzemet), first approved Sep 11, 1997, with 0 new uses approved and 0 published complete response letters.
| Study | Phase | Status | Posted |
|---|---|---|---|
| Dolasetron for the Prevention of CINV in Children With Acute Lymphoblastic LeukemiaChemotherapy Induced Nausea and Vomiting · Anhui Provincial Children's Hospital | — | Recruiting | Jan 1, 2025 |
| Sep 11, 1997 | AnzemetNDA 20623 · New molecular entity | Validus Pharms | 11 | Discontinued |
| Sep 11, 1997 | AnzemetNDA 20624 · New dosage form | Validus Pharms | 17 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
